<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mediators Inflamm</journal-id><journal-id journal-id-type="iso-abbrev">Mediators Inflamm</journal-id><journal-id journal-id-type="publisher-id">MI</journal-id><journal-title-group><journal-title>Mediators of Inflammation</journal-title></journal-title-group><issn pub-type="ppub">0962-9351</issn><issn pub-type="epub">1466-1861</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19365587</article-id><article-id pub-id-type="pmc">2667940</article-id><article-id pub-id-type="doi">10.1155/2009/932515</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Efficacy of Clopidrogel on Reperfusion and High-Sensitivity C-Reactive Protein in Patients with Acute Myocardial Infarction</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Akbulut</surname><given-names>Mehmet</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Kutlu</surname><given-names>Makbule</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ozbay</surname><given-names>Y&#x00131;lmaz</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Polat</surname><given-names>Veli</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bilen</surname><given-names>Mehmet Nail</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Baydas</surname><given-names>Adil</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Altas</surname><given-names>Yakup</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Cardiology, Faculty of Medicine, F&#x00131;rat University, 23100 Elaz&#x00131;&#x0011f;, Turkey</aff><aff id="I2"><sup>2</sup>Cardiology Clinic, Harput State Hospital, 23110 Elaz&#x00131;&#x0011f;, Turkey</aff><author-notes><corresp id="cor1">*Mehmet Akbulut: <email>makbulut@firat.edu.tr</email></corresp><fn fn-type="other"><p>Recommended by Charles Larry Campbell</p></fn></author-notes><pub-date pub-type="ppub"><year>2009</year></pub-date><pub-date pub-type="epub"><day>12</day><month>4</month><year>2009</year></pub-date><volume>2009</volume><elocation-id>932515</elocation-id><history><date date-type="received"><day>2</day><month>7</month><year>2008</year></date><date date-type="rev-recd"><day>30</day><month>12</month><year>2008</year></date><date date-type="accepted"><day>4</day><month>3</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Mehmet Akbulut et al.</copyright-statement><copyright-year>2009</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>We investigated the effects of clopidogrel on reperfusion and inflammatory process in STEMI. A total of 175 STEMI patients with similar clinical characteristics were included to this study. One was the standard pharmacological reperfusion therapy group (group 1, <italic>n</italic> : 90), who received 300 mg aspirin, 70 U/kg bolus, and 12 U/kg/hr continuous infusion of unfractioned heparin and accelerated t-PA. Clopidogrel 450 mg loading and 75 mg/d thereafter was added to standard reperfusion therapy in the other group (group 2, <italic>n</italic> : 85). The ST-segment resolution, CK-MB, and high-sensitive CRP (hs-CRP) parameters were measured. Complete ST resolution was observed in 32 patients (36.8%) in group 1 and 53 patients (63.8%) in group 2 (<italic>P</italic> &#x0003c; .001). Also in the first 24 hours, the CK-MB levels of patients in group 1 were significantly higher than those of group 2 (<italic>P</italic> = .001). The hs-CRP values were greater in group 1 than group 2 at 48th hour (gruop 1: 9.4 &#x000b1; 0.1 mg/L, group 2: 3.7 &#x000b1; 1.4 mg/L; <italic>P</italic> = .000). We concluded that adding clopidogrel to standard treatment in STEMI patients provided early reperfusion and suppression of inflammatory response.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p> Thromboxane and ADP, which are among the mediators of platelet activation and aggregation, play
a key role in initiating and propagating coronary thrombosis and are raised
during myocardial infarction. Simultaneous inhibition of both of these pathways
with the combination of clopidogrel and aspirin produces
greater antiplatelet effects than either agent alone [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>]. In recent reports,
dual antiplatelet therapy with aspirin and clopidogrel showed significant
improvements on prognosis in ST-elevating myocardial infarction (STEMI) [<xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>]. 
Moreover, this beneficial effect is not only limited to the acute phase, but
also extended to a 1-year follow-up period [<xref rid="B6" ref-type="bibr">6</xref>]. But substantial uncertainty
remained regarding the net effects of adding clopidogrel to aspirin upon the
reperfusion, acute inflammatory response, and ischemic events in this setting. 
In this study, we evaluated the effect of the addition of clopidogrel to
standard reperfusion protocol on reperfusion and acute inflammatory response.</p></sec><sec id="sec2"><title>2. Material
and Methods</title><sec sec-type="subsection" id="subsec2.1"><title>2.1. Patient Population</title><p> From December 2006 to January 2008, consecutive patients were enrolled who presented
with ischemic discomfort lasting &#x0003e;20 minutes at rest within 12 hours, before
randomization pain lasting &#x0003e;20 minutes, ST-segment elevation of at least 0.2 mV in at least two contiguous
precordial leads. The study was limited to only anteriorly located myocardial
infarction to homogenize the investigated population. The exclusion criteria
were conduction or rhythm abnormalities (bundle branch block, idioventricular
rhythm, etc.); any contraindication to thrombolytics [<xref rid="B7" ref-type="bibr">7</xref>]; early coronary
angiography (within first 48 hours) due to recurrent ischemia or failed
thrombolysis; those patients under the treatment of aspirin or thienopyridines; any contraindication to aspirin or
clopidogrel; past history of MI or coronary revascularization; presence of clinically
assessed heart failure (Killip II/III) or cardiogenic shock; hepatic failure;
renal failure (serum creatinine &#x0003e;2.5 mg/dL); thrombocytopenia (&#x0003c;100.000/mm<sup>3</sup>) and patients older than 70 years old were excluded.</p><p>The study protocol was approved by
institutional review board, and written informed consent was taken from all
patients.</p></sec><sec sec-type="subsection" id="subsec2.2"><title>2.2. Study Design</title><p>A total of 175 patients were included in the present
study and were allocated in 2 groups. One was the standard pharmacological
reperfusion therapy group (group 1, <italic>n</italic> : 90), consisting of patients who received
300 mg aspirin at first then 150 mg/d thereafter, 70 U/kg (maximum 5000 U)
bolus, and 12 U/kg/hr continuous infusion of unfractioned heparin and accelerated t-PA therapy (15 mg intravenous
bolus followed by an infusion of 0.75 mg/kg (maximum 50 mg) over 30 minutes,
followed by an infusion of 0.5 mg/kg (maximum 35 mg) over 60 minutes). 
Clopidogrel 450 mg loading and 75 mg/d thereafter was added to standard
reperfusion therapy in the other group (group 2, <italic>n</italic> : 85). The ST-segment
resolution within 120 minutes, CK-MB parameters within first 24 hours, and high-sensitive
C-reactive protein (hs-CRP) parameters within 48 hours were measured. Also patients
were examined for inhospital major and minor bleeding complications. All data
were evaluated by two investigators who are blinded to treatment.</p><sec sec-type="subsubsection" id="subsubsec2.2.1"><title>2.2.1. Electrocardiographic Analysis</title><p>Standard 12-lead electrocardiograms were
obtained at baseline and at 30-minute periods during the first120 minutes after
initiation of fibrinolytic therapy. ST-segment elevation was analyzed manually
with lens-intensified calipers to the nearest of 0.025 mV 20 milliseconds after the end of QRS complex with the PR segment as the reference
baseline from leads I, aVL, and V<sub>1</sub> through V<sub>6</sub> for
anterior infarction. The sum of ST deviation was measured at baseline and at
30, 60, 90, 120 minutes using previously described methods [<xref rid="B8" ref-type="bibr">8</xref>]. The percent
resolution of ST deviation from baseline to 30, 60, 90, 120 minutes was
calculated and categorized as complete (&#x02265;70%), partial (30% to 70%), or no
resolution (&#x02264;30%).</p></sec><sec sec-type="subsubsection" id="subsubsec2.2.2"><title>2.2.2. Blood Sampling</title><p>Blood samples were obtained for CK-MB and
hs-CRP analysis at 0, 4, 8, 12, 24 and 0, 24, 48 hours of admission, respectively. 
Biochemical and haematological parameters were measured by an Olympus AU 600
autoanalyzer (Olympus Optical Co., Ltd., Schimatsu-Mishima, Japan) and Bayer Advia 120 Cell CBC Counter Hematologia
autoanalyzer (Bayer Advia 120 CBC counter, NJ, USA). Hs-C-reactive protein was measured by
the high-sensitivity nephelometric method (Dade Behring, Marburg, Germany).</p></sec></sec><sec sec-type="subsection" id="subsec2.3"><title>2.3. Statistical Analysis</title><p>The SPSS for windows program (version 15.0) was
used for all data analysis. Study data were expressed as mean value &#x000b1; standard
deviation or percent values. Numerical variables were compared by Mann-Whiney <italic>U</italic>-test,
whereas nonnumerical ones were compared by Chi-squere test. Results with a <italic>P</italic> value less than .05 were considered statistically significant.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec sec-type="subsection" id="subsec3.1"><title>3.1. Baseline Characteristics</title><p>A total of 175 patients were included in the study
(group 1, <italic>n</italic> : 90; group 2, <italic>n</italic> : 85). Three
patients due to ischemic events in group 1 (2 failed thrombolysis, 1 heart
failure) and patients in group 2
were excluded from the study due to ischemic and hemorrhagic events (1 heart
failure, 1 gluteal hemorrhage). However, there were no important differences in
baseline clinical characteristics and initial therapy between the two treatment
groups. Clinical characteristics of the study groups were shown in <xref ref-type="table" rid="tab1">Table 1</xref>.</p></sec><sec sec-type="subsection" id="subsec3.2"><title>3.2. ST-Segment</title><p>Complete ST resolution was achieved in 32 of
patients (36.8%) in group 1 and 53 of patients (63.8%) in group 2 (<italic>P</italic> &#x0003c; .001)
at the end of 120 minutes (<xref ref-type="table" rid="tab2">Table 2</xref> and <xref ref-type="fig" rid="fig1">Figure 1</xref>). The difference between groups
started after 60th minute
of the therapy, and it became more significant at 120th minute (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p></sec><sec sec-type="subsection" id="subsec3.3"><title>3.3. CK-MB</title><p>Peak CK-MB values were reached at 10&#x02013;12th hours in group 1, whereas
in group 2 they were
at 8&#x02013;10th hours. Peak CK-MB value
was 233.5 &#x000b1; 145 U/L in group 1 and
132.5 &#x000b1; 122 U/L in group 2 (<italic>P</italic> = .01), and at the end of 24 hours CK-MB value
was 138 &#x000b1; 88 U/L in group 1, and 56 &#x000b1; 35 U/L in group 2 (<italic>P</italic> = .001) (<xref ref-type="table" rid="tab3">Table 3</xref>).</p></sec><sec sec-type="subsection" id="subsec3.4"><title>3.4. The hs-CRP</title><p>Although baseline hs-CRP values were similar at
baseline (group 1: 1.6 &#x000b1; 0.9 mg/L, group 2: 1.9 &#x000b1; 1.3 mg/L; <italic>P</italic> = .67), they were greater in
group 1 than group 2 at 48th hour (group 1: 9.4 &#x000b1; 0.1 mg/L, group 2: 3.7 &#x000b1; 1.4 mg/L; <italic>P</italic> = .000) (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p></sec><sec sec-type="subsection" id="subsec3.5"><title>3.5. Other Clinical Outcome</title><p>No death was observed in both groups. Failed
thrombolysis in two patients and heart failure in one patient were seen in
group 1; one patient with heart failure and one patient with major hemorrhage
(&#x02265;2 unit blood transfusion) were seen in group 2. However, there is no
significant difference between the groups with respect to these unfavorable
events (<italic>P</italic> &#x0003e; .05).</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>Platelet activation and aggregation play a key
role initiating and propagating coronary artery thrombosis, and antiplatelet
therapy improves outcomes across the spectrum of acute coronary syndromes. Beside
this, it was thought that simultaneous inhibition of platelet activation and
aggregation pathways with specific antiplatelet combinations might be more
efficient in acute coronary syndromes [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>]. We observed improvements in both
reperfusion and inflammatory response with the early addition of clopidogrel to
standard reperfusion therapy in STEMI patients in this study. Moreover, these
findings supported the hypothesis of dual antiplatelet inhibition with aspirin
and clopidogrel might be more beneficial in acute coronary syndrome.</p><p>Currently, there are promising developments in
the prevention of ischemic complications in sympthomatic atherothrombotic
cases. The CLARITY-TIMI 28 study demonstrated that the addition of clopidogrel
to aspirin in patients with STEMI receiving fibrinolytic therapy improved the
patency rate of the infarct-related artery after 48 hours and reduced ischemic
complications [<xref rid="B3" ref-type="bibr">3</xref>]. Among the patients in this trial who underwent percutaneous
coronary intervention (PCI), described in the PCI-CLARTY substudy, clopidogrel
pretreatment significantly reduced the incidence of cardiac death or ischemic
complications both before and after PCI [<xref rid="B9" ref-type="bibr">9</xref>]. In the COMMIT trial, the routine
addition of clopidogrel 75 mg/d to aspirin therapy for 4 weeks in patients with
acute myocardial infarction resulted in a 9% proportional reduction in death,
reinfarction, or stroke (<italic>P</italic> = .002) and a 7% proportional reduction in
death (<italic>P</italic> = .03) [<xref rid="B5" ref-type="bibr">5</xref>]. Even though no loading dose was used, the benefit of
clopidogrel therapy was seen almost immediately by an 11% proportional
reduction in mortality in the first 2 days after the initiation of therapy (<italic>P</italic> = .019)
[<xref rid="B5" ref-type="bibr">5</xref>]. The results of both CLARITY-TIMI 28 and COMMIT showed that adding
clopidogrel to aspirin and other standard treatments safely reduced mortality
and major vascular events in patients with acute myocardial infarction.</p><p>Beneficial effects of clopidogrel may arise
through some different proposed mechanisms. (i) Clopidogrel may facilitate initial fibrinolysis and thereby
improve early reperfusion with a glycoprotein IIb-IIIa inhibitor [<xref rid="B10" ref-type="bibr">10</xref>]-like
effect. (ii) Clopidogrel may exert its effects in myocardial infarction mainly
by preventing reocclusion or by limiting microvascular effects of platelet
activation rather than enhancing fibrinolysis [<xref rid="B5" ref-type="bibr">5</xref>]. While most of the benefit of
clopidogrel has been attributed to inhibition of platelet activation, blockage
of the P2Y12 receptor may also have pleotropic effects with respect to
endothelial cell function, leukocyte activation, and inflammation [<xref rid="B11" ref-type="bibr">11</xref>].</p><p>Previous studies have suggested some
anti-inflammatory properties of clopidogrel. A reduction in the number of
platelet-leukocyte interactions has been described [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>], and one study
reported a special benefit of the drug in reducing the augmented risk of
percutaneous interventions in patients with elevated levels of C-reactive
protein [<xref rid="B14" ref-type="bibr">14</xref>]. In another study, it was stated that clopidogrel pretreatment
attenuated the periprocedural increase in CRP by 65% [<xref rid="B15" ref-type="bibr">15</xref>]. Quinn et
al. said that clopidogrel pretreatment reduces platelet inflammatory marker expression in patients undergoing
PCI [<xref rid="B16" ref-type="bibr">16</xref>], and they also concluded that it might be very important for clinical
events. All these findings constituted an important clue for us to investigate
the limiting effect of clopidogrel in increment of high-sensitive C-reactive protein in STEMI and to verify
this. Moreover, we could not see another study in literature about this topic.</p><p>Activated
platelets have been clearly implicated in the tendency for microembolization
during acute coronary syndrome [<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>] and play an important role in the
inflammatory response. Studies have shown that activated platelets express the
CD40 ligand, a potent stimulus of vascular inflammation [<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>]. The CD40
ligand promotes platelet-leukocyte interactions [<xref rid="B19" ref-type="bibr">19</xref>] and induces tissue factor
expression [<xref rid="B21" ref-type="bibr">21</xref>], thus providing a link among inflammation, platelet activation,
embolization, and coagulation. The inhibition of subcellular platelet CD40
ligand by clopidogrel treatment may explain the mechanism of reduction in
inflammation as expressed by an attenuation in C-reactive protein increase
after acute STEMI. By the way, we think that large extensive clinical trials
are needed to exactly clarify the mechanisms of beneficial effects of
clopidogrel on clinical results in previous ones and that is what we have
determined in our study because the impressive improvement in clinical results
with added clopidogrel on aspirin requires some other mechanisms except for a
potent antiplatelet effect.</p></sec><sec id="sec5"><title>5. Limitations</title><p>The first and most important limitation is the small
study population and the lack of a placebo control group. Only the anteriorly
located STEMI patients were included to homogenize the study population, and a
fibrinolytic agent only rt-PA was used and this condition was an important
limiting factor for our study. Clopidogrel loading dose (450 mg) may be a
limitation. We think that different
dosages (300&#x02013;600 mg) should be
applied for both evaluations
of safety and efficacy because there is a correlation between loading dose and
time to reach maximal antiplatelet effect [<xref rid="B22" ref-type="bibr">22</xref>]. Another limiting factor of our
study was the restriction of the study with 48 hours. A long follow-up period
would be more useful to exactly realize all the efficiency and safety of
clopidogrel (major and minor hemorrhages
included) treatment. So that with long follow-up period, difference among the
groups of medical treatment, PCI and coronary artery bypass grefting in the direction of angiographic findings could
be clearly understood.</p></sec><sec id="sec6"><title>6. Conclusions</title><p>In conclusion, we found that addition of
clopidogrel to medical reperfusion therapy in STEMI had favorable effects on
reperfusion and suppression of hs-CRP. We think that these favorable clinical
and laboratory effects of dual antiplatelet therapy with clopidogrel are not only limited to
its antiplatelet effect, but also there may be some pleiotropic effects of
clopidogrel; those were not explained clearly. Large extensive studies are
needed to explain the complete effect of clopidogrel in acute STEMI.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregorini</surname><given-names>L</given-names></name><name><surname>Marco</surname><given-names>J</given-names></name></person-group><article-title>Ticlopidine and aspirin interactions</article-title><source><italic>Heart</italic></source><year>1997</year><volume>77</volume><issue>1</issue><fpage>11</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">9038687</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishkel</surname><given-names>GJ</given-names></name><name><surname>Aguirre</surname><given-names>FV</given-names></name><name><surname>Ligon</surname><given-names>RW</given-names></name><name><surname>Rocha-Singh</surname><given-names>KJ</given-names></name><name><surname>Lucore</surname><given-names>CL</given-names></name></person-group><article-title>Clopidogrel as adjunctive antiplatelet therapy during coronary stenting</article-title><source><italic>Journal of the American College of Cardiology</italic></source><year>1999</year><volume>34</volume><issue>7</issue><fpage>1884</fpage><lpage>1890</lpage><pub-id pub-id-type="pmid">10588198</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabatine</surname><given-names>MS</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Gibson</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2005</year><volume>352</volume><issue>12</issue><fpage>1179</fpage><lpage>1189</lpage><pub-id pub-id-type="pmid">15758000</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabatine</surname><given-names>MS</given-names></name><name><surname>Morrow</surname><given-names>DA</given-names></name><name><surname>Montalescot</surname><given-names>G</given-names></name><etal/></person-group><article-title>Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 trial</article-title><source><italic>Circulation</italic></source><year>2005</year><volume>112</volume><issue>25</issue><fpage>3846</fpage><lpage>3854</lpage><pub-id pub-id-type="pmid">16291601</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><collab>COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group</collab><article-title>Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial</article-title><source><italic>The Lancet</italic></source><year>2005</year><volume>366</volume><issue>9497</issue><fpage>1607</fpage><lpage>1621</lpage></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeymer</surname><given-names>U</given-names></name><name><surname>Gitt</surname><given-names>AK</given-names></name><name><surname>J&#x000fc;nger</surname><given-names>C</given-names></name><etal/></person-group><article-title>Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice</article-title><source><italic>European Heart Journal</italic></source><year>2006</year><volume>27</volume><issue>22</issue><fpage>2661</fpage><lpage>2666</lpage><pub-id pub-id-type="pmid">17043060</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Antman</surname><given-names>EM</given-names></name></person-group><article-title>ST-elevation myocardial infarction: management</article-title><source><italic>Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine</italic></source><year>2008</year><edition>8th edition</edition><publisher-loc>Philadelphia, Pa, USA</publisher-loc><publisher-name>Saunders/Elsevier</publisher-name><fpage>1233</fpage><lpage>1299</lpage></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lemos</surname><given-names>JA</given-names></name><name><surname>Antman</surname><given-names>EM</given-names></name><name><surname>Giugliano</surname><given-names>RP</given-names></name><etal/></person-group><article-title>St-segment resolution and infarct-related artery patency and flow after thrombolytic therapy</article-title><source><italic>The American Journal of Cardiology</italic></source><year>2000</year><volume>85</volume><issue>3</issue><fpage>299</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">11078296</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabatine</surname><given-names>MS</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Gibson</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study</article-title><source><italic>The Journal of the American Medical Association</italic></source><year>2005</year><volume>294</volume><issue>10</issue><fpage>1224</fpage><lpage>1232</lpage><pub-id pub-id-type="pmid">16143698</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antman</surname><given-names>EM</given-names></name><name><surname>Giugliano</surname><given-names>RP</given-names></name><name><surname>Gibson</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial</article-title><source><italic>Circulation</italic></source><year>1999</year><volume>99</volume><issue>21</issue><fpage>2720</fpage><lpage>2732</lpage><pub-id pub-id-type="pmid">10351964</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinn</surname><given-names>MJ</given-names></name><name><surname>Plow</surname><given-names>EF</given-names></name><name><surname>Topol</surname><given-names>EJ</given-names></name></person-group><article-title>Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?</article-title><source><italic>Circulation</italic></source><year>2002</year><volume>106</volume><issue>3</issue><fpage>379</fpage><lpage>385</lpage><pub-id pub-id-type="pmid">12119257</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Storey</surname><given-names>RF</given-names></name><name><surname>Judge</surname><given-names>HM</given-names></name><name><surname>Wilcox</surname><given-names>RG</given-names></name><name><surname>Heptinstall</surname><given-names>S</given-names></name></person-group><article-title>Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin</article-title><source><italic>Thrombosis and Haemostasis</italic></source><year>2002</year><volume>88</volume><issue>3</issue><fpage>488</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">12353080</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klinkhardt</surname><given-names>U</given-names></name><name><surname>Graff</surname><given-names>J</given-names></name><name><surname>Harder</surname><given-names>S</given-names></name></person-group><article-title>Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model</article-title><source><italic>Clinical Pharmacology &#x00026; Therapeutics</italic></source><year>2002</year><volume>71</volume><issue>3</issue><fpage>176</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">11907492</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chew</surname><given-names>DP</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Robbins</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Effect of <italic>clopidogrel</italic> added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein</article-title><source><italic>The American Journal of Cardiology</italic></source><year>2001</year><volume>88</volume><issue>6</issue><fpage>672</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">11564394</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vivekananthan</surname><given-names>DP</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Chew</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Effect of <italic>clopidogrel</italic> pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention</article-title><source><italic>The American Journal of Cardiology</italic></source><year>2004</year><volume>94</volume><issue>3</issue><fpage>358</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">15276105</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinn</surname><given-names>MJ</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Zidar</surname><given-names>F</given-names></name><etal/></person-group><article-title>Effect of <italic>clopidogrel</italic> pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention</article-title><source><italic>The American Journal of Cardiology</italic></source><year>2004</year><volume>93</volume><issue>6</issue><fpage>679</fpage><lpage>684</lpage><pub-id pub-id-type="pmid">15019868</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>MJ</given-names></name><name><surname>Thomas</surname><given-names>AC</given-names></name><name><surname>Knapman</surname><given-names>PA</given-names></name><name><surname>Hangartner</surname><given-names>JR</given-names></name></person-group><article-title>Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death</article-title><source><italic>Circulation</italic></source><year>1986</year><volume>73</volume><issue>3</issue><fpage>418</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">3948352</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frink</surname><given-names>RJ</given-names></name><name><surname>Rooney</surname><given-names>PA</given-names><suffix>Jr.</suffix></name><name><surname>Trowbridge</surname><given-names>JO</given-names></name><name><surname>Rose</surname><given-names>JP</given-names></name></person-group><article-title>Coronary thrombosis and platelet/fibrin microemboli in death associated with acute myocardial infarction</article-title><source><italic>British Heart Journal</italic></source><year>1988</year><volume>59</volume><issue>2</issue><fpage>196</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">3342160</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henn</surname><given-names>V</given-names></name><name><surname>Slupsky</surname><given-names>JR</given-names></name><name><surname>Gr&#x000e4;fe</surname><given-names>M</given-names></name><etal/></person-group><article-title>CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells</article-title><source><italic>Nature</italic></source><year>1998</year><volume>391</volume><issue>6667</issue><fpage>591</fpage><lpage>594</lpage><pub-id pub-id-type="pmid">9468137</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Topol</surname><given-names>EJ</given-names></name></person-group><article-title>Scientific and therapeutic advances in antiplatelet therapy</article-title><source><italic>Nature Reviews Drug Discovery</italic></source><year>2003</year><volume>2</volume><issue>1</issue><fpage>15</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">12509756</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mach</surname><given-names>F</given-names></name><name><surname>Sch&#x000f6;nbeck</surname><given-names>U</given-names></name><name><surname>Bonnefoy</surname><given-names>J-Y</given-names></name><name><surname>Pober</surname><given-names>JS</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name></person-group><article-title>Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor</article-title><source><italic>Circulation</italic></source><year>1997</year><volume>96</volume><issue>2</issue><fpage>396</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">9244201</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Popma</surname><given-names>JJ</given-names></name><name><surname>Baim</surname><given-names>DS</given-names></name><name><surname>Resnic</surname><given-names>FS</given-names></name></person-group><article-title>Percutaneous coronary and valvular intervention</article-title><source><italic>Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine</italic></source><year>2008</year><edition>8th edition</edition><publisher-loc>Philadelphia, Pa, USA</publisher-loc><publisher-name>Saunders/Elsevier</publisher-name><fpage>1419</fpage><lpage>1456</lpage></element-citation></ref></ref-list></back><floats-group><fig id="fig1" position="float"><label>Figure 1</label><caption><p>120 minute ST-segment resolution.</p></caption><graphic xlink:href="MI2009-932515.001"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Patient number with ST-segment resolution in the course of time.</p></caption><graphic xlink:href="MI2009-932515.002"/></fig><fig id="fig3" position="float"><label>Figure 3</label><caption><p>hs-CRP levels of the patients in the groups during the first 48 hours.</p></caption><graphic xlink:href="MI2009-932515.003"/></fig><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p> Baseline characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> Characteristics </th><th align="center" rowspan="1" colspan="1"> Group
1 (<italic>n</italic> : 87)</th><th align="center" rowspan="1" colspan="1"> Group
2 (<italic>n</italic> : 83)</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> value </th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Mean age (year)</td><td align="center" rowspan="1" colspan="1">57 &#x000b1; 7</td><td align="center" rowspan="1" colspan="1">56 &#x000b1; 5</td><td align="center" rowspan="1" colspan="1">.31</td></tr><tr><td align="left" rowspan="1" colspan="1">Men (%)</td><td align="center" rowspan="1" colspan="1">79.3</td><td align="center" rowspan="1" colspan="1">80.7</td><td align="center" rowspan="1" colspan="1">.48</td></tr><tr><td align="left" rowspan="1" colspan="1">Time for symptom to lytic (h)</td><td align="center" rowspan="1" colspan="1">2.7 &#x000b1; 2</td><td align="center" rowspan="1" colspan="1">2.6 &#x000b1; 1</td><td align="center" rowspan="1" colspan="1">.56</td></tr><tr><td align="left" rowspan="1" colspan="1">Presentation</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;</italic>Heart rate (beat/min)</td><td align="center" rowspan="1" colspan="1">75 &#x000b1; 14</td><td align="center" rowspan="1" colspan="1">74 &#x000b1; 12</td><td align="center" rowspan="1" colspan="1">.37</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;</italic>Systolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">133 &#x000b1; 14</td><td align="center" rowspan="1" colspan="1">135 &#x000b1; 16</td><td align="center" rowspan="1" colspan="1">.31</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;</italic>Diastolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">73 &#x000b1; 11</td><td align="center" rowspan="1" colspan="1">75 &#x000b1; 15</td><td align="center" rowspan="1" colspan="1">.29</td></tr><tr><td align="left" rowspan="1" colspan="1">History (%)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;</italic>Current smoker</td><td align="center" rowspan="1" colspan="1">44.8</td><td align="center" rowspan="1" colspan="1">44.6</td><td align="center" rowspan="1" colspan="1">.51</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;</italic>Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">17.2</td><td align="center" rowspan="1" colspan="1">19.3</td><td align="center" rowspan="1" colspan="1">.44</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;</italic>Hypertension</td><td align="center" rowspan="1" colspan="1">29.9</td><td align="center" rowspan="1" colspan="1">32.5</td><td align="center" rowspan="1" colspan="1">.35</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;</italic>Hyperlipidemia</td><td align="center" rowspan="1" colspan="1">27.6</td><td align="center" rowspan="1" colspan="1">31.3</td><td align="center" rowspan="1" colspan="1">.35</td></tr><tr><td align="left" rowspan="1" colspan="1">High TIMI risk score (&#x02265;5)</td><td align="center" rowspan="1" colspan="1">13.8</td><td align="center" rowspan="1" colspan="1">14.8</td><td align="center" rowspan="1" colspan="1">.33</td></tr><tr><td align="left" rowspan="1" colspan="1">Medication during hospitalization (%)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;</italic>
<italic>&#x003b2;</italic>-blocker</td><td align="center" rowspan="1" colspan="1">93</td><td align="center" rowspan="1" colspan="1">94</td><td align="center" rowspan="1" colspan="1">.50</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;</italic>Statins</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">93</td><td align="center" rowspan="1" colspan="1">.51</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;</italic>ACE-I or ARB</td><td align="center" rowspan="1" colspan="1">73</td><td align="center" rowspan="1" colspan="1">74</td><td align="center" rowspan="1" colspan="1">.43</td></tr></tbody></table></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p> Number of patients with
resolution in 120th minute.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">
</th><th align="center" rowspan="1" colspan="1">Group 1 (<italic>n</italic> : 87)</th><th align="center" rowspan="1" colspan="1">Group 2 (<italic>n</italic> : 83)</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">&#x0003e;70%</td><td align="center" rowspan="1" colspan="1">36.8 (32)</td><td align="center" rowspan="1" colspan="1">63.8 (53)</td><td align="center" rowspan="1" colspan="1">.001</td></tr><tr><td align="left" rowspan="1" colspan="1">30&#x02013;70%</td><td align="center" rowspan="1" colspan="1">49.4 (43)</td><td align="center" rowspan="1" colspan="1">27.7 (23)</td><td align="center" rowspan="1" colspan="1">.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;30%</td><td align="center" rowspan="1" colspan="1">13.8 (12)</td><td align="center" rowspan="1" colspan="1">8.4 (7)</td><td align="center" rowspan="1" colspan="1">.01</td></tr></tbody></table></table-wrap><table-wrap id="tab3" position="float"><label>Table 3</label><caption><p> CK-MB (U/L) levels of the patients in the groups during
the first 24 hours.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">
</th><th align="center" rowspan="1" colspan="1">0 hour</th><th align="center" rowspan="1" colspan="1">4th hour</th><th align="center" rowspan="1" colspan="1">8th hour</th><th align="center" rowspan="1" colspan="1">12th hour</th><th align="center" rowspan="1" colspan="1">24th hour</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Group I</td><td align="center" rowspan="1" colspan="1">29.2 &#x000b1; 23</td><td align="center" rowspan="1" colspan="1">106.4 &#x000b1; 54</td><td align="center" rowspan="1" colspan="1">193.2 &#x000b1; 125</td><td align="center" rowspan="1" colspan="1">233.5 &#x000b1; 145</td><td align="center" rowspan="1" colspan="1">138 &#x000b1; 88</td></tr><tr><td align="left" rowspan="1" colspan="1">Group II</td><td align="center" rowspan="1" colspan="1">28.5 &#x000b1; 22</td><td align="center" rowspan="1" colspan="1">55.4 &#x000b1; 35</td><td align="center" rowspan="1" colspan="1">132.5 &#x000b1; 122</td><td align="center" rowspan="1" colspan="1">111.3 &#x000b1; 27</td><td align="center" rowspan="1" colspan="1">56 &#x000b1; 35</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>P</italic> value</td><td align="center" rowspan="1" colspan="1">.66</td><td align="center" rowspan="1" colspan="1">.006</td><td align="center" rowspan="1" colspan="1">.01</td><td align="center" rowspan="1" colspan="1">.001</td><td align="center" rowspan="1" colspan="1">.001</td></tr></tbody></table></table-wrap></floats-group></article>